Skip to main content
. 2020 Jun 23;5(Suppl 3):e000820. doi: 10.1136/esmoopen-2020-000820

Table 7.

Radiation oncology priorities for lung disease

High priority Medium priority Low priority
Radiotherapy for inoperable stage II to III cancers, with contraindications for chemotherapy. SABR - SBRT for stage I cancers
Concomitant (preferred) chemo-radiotherapy for inoperable NSCLC Stage II/III. - Adjuvant PORT for R1 resection, if indicated in NSCLC could be considered at the end of adjuvant chemotherapy or delayed up to 3 months from surgery Adjuvant PORT N2 R0, if indicated in NSCLC should be discussed and if retained considered at the end of adjuvant chemotherapy or delayed up to 3 months from surgery
Concomitant (preferred) chemo-radiotherapy for SCLC limited disease PCI in limited SCLC after chemotherapy PCI in extensive stage SCLC after chemotherapy should be replaced by MRI active surveillance
Superior vein cave obstruction or significant haemoptysis, spinal cord compression or any threatening lesion amenable to radiation therapy

NSCLC, non-small cell lung cancer; PCI, prophylactic cranial irradiation; PORT, post-operative radiation therapy; SABR, stereotactic ablative radiotherapy; SBRT, stereotactic body radiotherapy; SCLC, small cell lung cancer.